Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 19.384
Filter
1.
Bol. méd. postgrado ; 36(2): 21-25, dic.2020. tab, graf
Article in Spanish | LILACS (Americas), LIVECS | ID: biblio-1117893

ABSTRACT

El síndrome de lisis tumoral (SLT) es una complicación potencialmente letal provocada por la liberación masiva de ácidos nucleicos, potasio y fosfato hacia la circulación sistémica lo cual se asocia a graves trastornos del metabolismo hidroelectrolítico. Se realizó una revisión retrospectiva de historias clínicas con el objetivo de describir las características clínicas de los pacientes con sospecha de SLT que ingresaron al Servicio de Medicina Interna del Hospital General Universitario Dr. Luis Gómez López durante el lapso 2017-2018. El 50% de los pacientes tenían una edad comprendida entre 51 y 70 años, siendo el 65% de sexo femenino. Los canceres más frecuentemente encontrados fueron el cáncer de mama (29%), cáncer gástrico (15%) y el linfoma no Hodgkin (12%). Todos los pacientes presentaron al menos tres de las manifestaciones clínicas asociadas al SLT entre las cuales se encuentran náuseas, vómitos, anorexia, debilidad, calambres, hiperreflexia, oliguria, anuria, hematuria, hipotensión, convulsiones y deshidratación. El 46% de los pacientes presentaron hiperpotasemia, mientras que 36% mostraron hipocalcemia y 18% hiperfosfatemia. El 76% de los pacientes cursaron con una creatinina > 1,4 mg/dl. El diagnóstico definitivo de SLT no fue posible realizarlo en ninguno de los pacientes incluidos en este estudio debido a la falta de estudios paraclínicos necesarios para satisfacer los criterios según los lineamientos internacionales(AU)


Tumor lysis syndrome (TLS) is a potentially lethal complication due to massive release of nucleic acids, potassium and phosphate into the systemic circulation which is associated with severe hydroelectrolitic metabolic disorders. A retrospective review of clinical charts was performed in order to describe clinical characteristics of patients with possible TLS that were admitted to the Servicio de Medicina Interna of the Hospital General Universitario Dr. Luis Gómez López during the period 2017-2018. The results show that 50% of patients were between 51 and 70 years old and 65% were female. Breast cancer (29%), stomach cancer (15%) and Non-Hodgkin lymphoma (12%) were more frequent in patients with possible TLS. All patients showed at least three of the clinical features commonly associated with TLS such as nausea, vomiting, anorexia, weakness, cramps, hyperreflexia, oliguria, anuria, hematuria, hypotension, convulsion and dehydration. 46% of patients had hyperkalemia, 36% hypocalcemia and 18% hyperphosphatemia. Creatinine levels > 1,4 mg/dl were seen in 76% of patients. Definitive diagnosis of TLS was not possible in any of the patients included in this study due to the lack of laboratory studies required according to international guidelines(AU)


Subject(s)
Humans , Phosphates , Potassium , Radiotherapy , Breast Neoplasms , Nucleic Acids , Tumor Lysis Syndrome/physiopathology , Drug Therapy , Drug Prescriptions , Critical Care , Hematology , Internal Medicine , Medical Oncology
2.
Rev. Asoc. Med. Bahía Blanca ; 30(1): 9-19, 20 de junio de 2020.
Article in Spanish | LILACS (Americas), BINACIS | ID: biblio-1099862

ABSTRACT

Introducción: La neutropenia febril es una urgencia infectológica con agentes etiológicos diversos. La causa más frecuente es la postquimioterapia, con una incidencia del 80%en inmunocomprometidos. Requiere el uso de antimicrobianos de amplio espectro, que originan mayores gastos en el sistema de salud. Objetivos: identificar los agentes microbiológicos en pacientes con neutropenia febril internados en el Hospital de la Asociación Médica de Bahía Blanca "Dr.Felipe Glasman" (HAMBB), en el periodo enero-diciembre de 2017; evaluar la sensibilidad y resistencia antimicrobiana; determinar el porcentaje de rédito de los cultivos. Materiales y Métodos: Estudio retrospectivo, descriptivo. Se obtuvieron datos de historias clínicas y de registros informatizados de los pacientes hospitalizados por neutropenia febril. Resultados: Se analizaron 52 episodios de 49 de pacientes. Las patologías de base fueron: tumores sólidos (54%); oncohematológicos (36%); enfermedades no neoplásicas (8%). El episodio febril fue postquimioterapia (48 %): por infección (35%); otras causas (17%). El 31% de los episodios postquimioterapia ocurrieron postratamiento (7-15 días). Los cultivos fueron negativos en el 69%. Se identificaron E.coli (15%); S.aureus (8%), P.aeruginosa (4%); 2% enterobacter (2%); E.faecalis ( 2%). Sensibilidad antibiótica: E.coli sensible a aminoglucósidos y fluoroquinolonas en el 87,5%, con resistencia de 50% para betalactámicos; a betalactámicos+IBL, cefalosporinas de 1° generación y cotrimoxazol (37,5%). S.aureus, E.faecalis, Enterobacter y P. aeruginosa fueron 100% sensibles a los antibióticos testeados. Conclusiones: El mayor porcentaje: bacterias Gram (-); principal agente causal: E. coli; principal agente Gram (+): S. aureus. La mayoría fueron pacientes con tumores sólidos. El 50 % de los episodios fue posterior postquimioterapia. El mayor rédito se obtuvo en hemocultivos. La mayor parte de los gérmenes fueron sensibles a la terapéutica empírica utilizada en nuestro hospital. (AU)


Introduction: Febrile neutropenia is an infectious emergency with diverse etiological agents. The most frequent cause is post-chemotherapy, with an incidence of 80% in immunocompromised patients. It requires the use of broadspectrum antimicrobials, which lead to higher expenses in the health system. Objectives: To identify the microbiological agents in patients with febrile neutropenia admitted to Bahía Blanca Medical Association "Dr. Felipe Glasman " Hospital (HAMBB) in the January-December 2017 period; to evaluate antimicrobial susceptibility and resistance; to determine the percentage of positive cultures. Materials and Methods: Retrospective, descriptive study. Data from medical records and computerized records of patients hospitalized for febrile neutropenia were obtained. Results: 52 episodes from 49 patients were analyzed. Underlying pathologies were: solid tumors (54%); oncohaematological (36%); non-neoplastic diseases (8%). The febrile episode was postchemotherapy (48%); due to infection (35%); other causes (17%). Thirty one per cent (31%) of post-chemotherapy episodes occurred after treatment (7-15 days). Cultures were negative in 69% of the cases. We could identify E.coli (15%); S.aureus (8%), P. aeruginosa (4%); 2% enterobacter (2%); E.faecalis (2%). Antibiotic susceptibility: E.coli sensitive to aminoglycosides and fluoroquinolones in 87.5%, with 50% resistance to betalactams; to beta-lactamases + IBL, 1st generation cephalosporins and cotrimoxazole (37.5%). S.aureus, E.faecalis, Enterobacter and P. aeruginosa were 100% susceptible to the antibiotics tested. Conclusions: The highest percentage: Gram bacteria (-); main causal agent: E. coli; Main agent Gram (+): S. aureus. The majority were patients with solid tumors. 50% of the episodes were post-chemotherapy. The occurrence was obtained in blood cultures. Most germs were susceptible to the empirical therapy used in our hospital. (AU)


Subject(s)
Humans , Febrile Neutropenia/drug therapy , Drug Therapy , Drug-Related Side Effects and Adverse Reactions/complications
3.
Rev. argent. mastología ; 39(142): 52-90, jun. 2020. graf
Article in Spanish | LILACS (Americas) | ID: biblio-1104088

ABSTRACT

El cáncer de mama Estadio IV se define como la diseminación de células tumorales más allá de la mama, la pared torácica y los ganglios linfáticos regionales. Globalmente, 5-10% de las mujeres tienen metástasis al momento del diagnóstico y hasta un 30% de aquellas con estadios tempranos al inicio desarrollará metástasis en algún momento. Se estima una mediana de sobrevida global en cáncer de mama metastásico de 3 años, con un intervalo que va desde pocos meses hasta muchos años, y una sobrevida a 5 años que ronda el 25%. Continúa siendo una enfermedad tratable pero no curable. Los objetivos terapéuticos en enfermedad metastásica principalmente son: prolongación de la sobrevida global y libre de enfermedad, disminución de síntomas y complicaciones asociadas al cáncer y mejoras en la calidad de vida de las pacientes. En la actualidad, estas metas son alcanzadas principalmente con la utilización de terapias sistémicas como la quimioterapia, la hormonoterapia o el uso de agentes biológicos. En algunas circunstancias, el tratamiento locorregional también contribuye a lograr estos objetivos. La elección del tratamiento sistémico está principalmente determinada por la biología tumoral, ya que esto permite el empleo de terapias dirigidas. En los tumores Luminales, deberá emplearse hormonoterapia, sola o en asociación con otros esquemas. En tumores her2+, se indicará, de ser posible, como primera línea de tratamiento doble bloqueo anti-her más quimioterapia. El subgrupo de peor pronóstico está representado por los tumores Triple Negativos, para los cuales no existen blancos terapéuticos dirigidos. En este caso, se utilizará quimioterapia. Se deberá usar terapia de mantenimiento luego de lograr el control de la enfermedad en tumores Luminales y her2+. El rol del tratamiento locorregional en cáncer de mama metastásico continúa siendo un tema de debate. Actualmente, algunos estudios sugieren que podrían obtenerse algunos beneficios, aunque aún hacen falta más datos para sostener su indicación. Deberá garantizarse un abordaje multidisciplinario y un seguimiento cercano de estas pacientes, con el fin de valorar la respuesta al tratamiento, la aparición de toxicidad inaceptable y las condiciones de calidad de vida


Stage IV breast cancer is defined as the spread of tumor cells beyond the breast, chest wall, and regional lymph nodes. Globally, 5-10% of women have metastases at diagnosis, and up to 30% of those with early stages of onset will develop metastases at some point. A median overall survival in metastatic breast cancer of 3 years is estimated, with an interval ranging from a few months to many years, and a 5-year survival of around 25%. It remains a treatable but not curable disease. The therapeutic goals in metastatic disease are mainly: prolongation of global and disease-free survival, decrease in symptoms and complications associated with cancer, and improvements in the quality of life of patients. At present, these goals are mainly achieved with the use of systemic therapies such as chemotherapy, hormonal therapy or the use of biological agents. In some circumstances locoregional treatment also contributes to achieving these goals. The choice of systemic treatment is mainly determined by tumor biology, since this allows the use of targeted therapies. In Luminal tumors, hormone therapy should be used, alone or in association with other schemes. In her2+ tumors, double blocking anti-her plus chemotherapy will be indicated if possible as the first line of treatment. The worst prognosis subgroup is represented by Triple Negative tumors for which there are no targeted therapeutic targets. In this case chemotherapy will be used. Maintenance therapy should be used after achieving control of the disease in Luminal tumors and her2+. The role of locoregional treatment in metastatic breast cancer continues to be a matter of debate. Currently some studies suggest that some benefits could be obtained although more data are still needed to support its indication. A multidisciplinary approach and close monitoring of these patients should be guaranteed in order to assess the response to treatment, the appearance of unacceptable toxicity and quality of life conditions


Subject(s)
Phenobarbital , Breast Neoplasms , Drug Therapy
4.
Arch. argent. pediatr ; 118(2): e162-e165, abr. 2020. ilus
Article in Spanish | LILACS (Americas), BINACIS | ID: biblio-1100422

ABSTRACT

Los sarcomas de partes blandas en menores de 2 años son infrecuentes. Durante 2007-2017, 445 pacientes con sarcomas de partes blandas fueron tratados en nuestra Institución; 6 (el 0,5 %) eran menores de 2 años. Se analizaron los resultados clínicos y oncológicos en este grupo. La edad media de diagnóstico fue 15 meses. Cuatro eran varones y 2, mujeres. El seguimiento promedio fue 29 meses. El fibrosarcoma (n = 4) fue la variedad más frecuente. Cinco fueron tratados con cirugía de conservación del miembro; al restante se le realizó amputación. Todos realizaron tratamiento adyuvante con quimioterapia. La supervivencia a 24 meses fue del 100 %. Dos pacientes presentaron recidiva local; ambos casos, antes de los 24 meses.El tratamiento quirúrgico asociado a la quimioterapia impresiona ser la mejor opción terapéutica. La proporción de recurrencia local es alta para este grupo de pacientes luego de la cirugía de conservación del miembro.


Soft tissue sarcomas in children under 2 years of age are infrequent. During 2007-2017, a total of 445 patients diagnosed with soft tissue sarcomas were treated at our institution, 6 (0.5 %) were under 2 years. We analysed clinical and oncologic outcomes in this select group. The mean age of diagnosis was 15 months. Four patients were male and 2 female. The mean follow-up time was 29 months. Fibrosarcoma (n = 4) was the most frequent diagnosis. Five patients were treated with limb salvage surgery, and the remaining one had to undergo amputation. All patients received adjuvant treatment with chemotherapy. The 24-month survival rate was 100 %. Two patients presented a local recurrence before 24-months follow-up. Surgical treatment associated with chemotherapy seems to be the best therapeutic option. Local recurrence rate after limb salvage surgery is high for this group of patients


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Sarcoma/surgery , Drug Therapy , Rhabdomyosarcoma/surgery , Rhabdomyosarcoma/therapy , Sarcoma/radiotherapy , Sarcoma/therapy , Retrospective Studies
5.
J. Health Biol. Sci. (Online) ; 8(1): 1-9, 20200101. ilus
Article in Portuguese | LILACS (Americas) | ID: biblio-1118061

ABSTRACT

Objetivo: verificar os principais agravos bucais e o desenvolvimento da dentição em indivíduos diagnosticados com leucemia e submetidos às terapias antineoplásicas. Métodos: trata-se de uma revisão integrativa da literatura fundamentada em artigos científicos, classificados de acordo com o nível de evidência (NE) científica proposto pelo Oxford Centre Evidence Based Medicine, 2009. A pergunta norteadora do presente estudo compreende: Quais as principais manifestações orais e alterações no desenvolvimento da dentição em pacientes com leucemia? Resultados: 14 estudos foram incluídos, publicados entre os anos de 2003 e 2019. As principais alterações bucais apresentadas foram morfologia anormal do esmalte e das raízes (taurodontia, hipodontia, microdontia, hipoplasia, raízes curtas), agenesias, sangramento gengival, mucosites, xerostomia e desenvolvimento dental tardio. Conclusões: torna-se necessário o acompanhamento multidisciplinar em face da condução do tratamento leucêmico, na qual a presença do cirurgião-dentista é crucial para a manutenção da saúde bucal.


Objective: To verify the main oral diseases and the development of dentition in individuals diagnosed with leukemia and submitted to antineoplastic therapies. Methods: This is an integrative review of the literature based on scientific articles, classified according to the level of scientific evidence (NE) proposed by Oxford Center Evidence Based Medicine, 2009. The guiding question of the present study comprises: What are the main oral manifestations disorders and changes in teething development in patients with leukemia? Results: A total of fourteen studies were included, published between 2003 and 2019. The main oral alterations presented were: abnormal enamel and root morphology (taurodontics, hypodontia, microdontia, hypoplasia, short roots), agenesis, gingival bleeding, mucositis, xerostomia and late dental development. Conclusions: It is necessary to have multidisciplinary follow-up when conducting leukemic treatment, in which the presence of the dental surgeon is crucial for maintaining oral health.


Subject(s)
Leukemia , Radiotherapy , Bone Marrow Transplantation , Drug Therapy
6.
J. Health Biol. Sci. (Online) ; 8(1): 1-8, 01/01/2020. ilus
Article in Portuguese | LILACS (Americas) | ID: biblio-1103268

ABSTRACT

Objetivo: apresentar os aspectos epidemiológicos, clínicos e terapêuticos da COVID-19. Método: trata-se de uma revisão narrativa da literatura, realizada por meio da busca por publicações científicas indexadas nas bases de dados: PubMed, Europe PMC, ScienceDirect e SciELO. Os seguintes descritores foram utilizados: "COVID-19", "diagnosis", "drug therapy", "pandemics" e "SARS-CoV-2". Ao final, foram selecionadas 32 publicações. Resultados: a análise dos estudos evidenciou que a rápida disseminação da COVID-19 pode estar relacionada à forma de transmissão, bem como à capacidade de o vírus permanecer estável em aerossóis e superfícies contaminadas. O diagnóstico de COVID-19 tem sido realizado mediante observação dos sintomas, e por um método de biologia molecular. Ainda não há medicamentos específicos e uma vacina contra a doença. No entanto, alguns medicamentos existentes no mercado, indicados para tratar outras patologias, estão sendo considerados como promissoras terapêuticas para a doença. Conclusão: a pandemia de COVID-19 já se configura como o maior desafio para saúde pública do século XXI, com elevadas taxas de morbidade e mortalidade em todo o mundo, principalmente devido à alta infectividade, e à severidade das manifestações clínicas em populações de risco, sendo mais letal. A falta de evidências científicas conclusivas quanto à eficácia e à segurança dos medicamentos off label no tratamento da doença tem gerado incertezas nos procedimentos de decisão clínica, sendo primordial a realização de ensaios clínicos randomizados, envolvendo um maior número de pacientes.


Objective: to present the epidemiological, clinical and therapeutic aspects of COVID-19. Method: this is a narrative review of the literature, performed through the search of scientific publications indexed in the databases: PubMed, Europe PMC, ScienceDirect and SciELO. The following descriptors were used: "COVID-19", "diagnosis", "drug therapy", "pandemics" and "SARS-CoV-2". At the end, 32 publications were selected. Results: the analysis of the studies showed that the rapid spread of COVID-19 may be related to the form of transmission, as well as to the ability of the virus to remain stable in aerosols and contaminated surfaces. The diagnosis of COVID-19 has been made through observation of symptoms, and by a molecular biology method. There are still no specific drugs and a vaccine against the disease. However, some drugs on the market, indicated to treat other pathologies, are being considered as promising therapeutics for the disease. Conclusion: the COVID-19 pandemic is already configured as the greatest public health challenge of the 21st century, with high morbidity and mortality rates worldwide, mainly due to high infectivity, and severity of clinical manifestations in populations at risk, being more lethal. The lack of conclusive scientific evidence regarding the efficacy and safety of off-label medications in the treatment of the disease, has generated uncertainties in clinical decision-making procedures, and it is essential to carry out randomized clinical trials, involving a greater number of patients.


Subject(s)
Coronavirus Infections , Betacoronavirus , Drug Therapy , Pandemics
7.
J. Health Biol. Sci. (Online) ; 8(1): 1-7, 01/01/2020. ilus
Article in Portuguese | LILACS (Americas) | ID: biblio-1100049

ABSTRACT

Objetivo: determinar drogas e medicamentos sugeridos para o tratamento do covid-19. Métodos: nesta pesquisa, foram utilizados os estudos que estavam definidos como ainda não recrutando e em fase de recrutamento, disponíveis no site Clinical Trials, em que foram inseridos os meios de intervenção, por meio de drogas e medicamentos. Resultados: com os filtros aplicados, os estudos em que ainda não estavam recrutando somaram um total de 131, e nos estudos que estavam em fase de recrutamento, existiam 126 análises. Conclusão: de acordo com a busca ativa, tanto nos estudos ainda não recrutando, quanto nos que estavam em recrutamento, a hidroxicloroquina é o medicamento que está sendo mais investigado.


Objective: to determine suggested drugs and medications for the treatment of covid-19. Methods: in this research, studies that were defined as not yet recruiting and in the recruitment phase were used, available on the Clinical Trials website, in which the means of intervention were inserted, using drugs and medications. Results: with the filters applied, the studies in which they were not yet recruiting totaled 131, and in the studies that were in the recruitment phase, there were 126 analyzes. Conclusion: according to the active search, both in studies not yet recruiting, and in those that were being recruited, hydroxychloroquine is the drug that is being investigated the most.


Subject(s)
Coronavirus Infections , Drug Therapy
8.
Rev. cienc. cuidad ; 17(1): 57-70, 2020.
Article in Spanish | LILACS (Americas), COLNAL | ID: biblio-1051725

ABSTRACT

Identificar conocimientos y prácticas del personal de salud respecto al uso de medicamentos en vías y condiciones diferentes a las establecidas en la ficha técnica. Método: Estudio cuantitativo de tipo descriptivo y corte transversal en dos fases: la primera consistió en una revisión de la literatura en donde se incluyeron de forma inicial 82 artículos, de los cuales ocho fueron elegidos para la revisión; la segunda fase estuvo conformada por 31 participantes que trabajaban en Instituciones de Salud; fueron seleccionados de forma no probabilista secuencial, a quienes se les aplicó un cuestionario, para identificar conocimientos y prácticas desarrolladas, el cual fue evaluado por 3 profesores expertos en la temática; también se realizó una prueba piloto. Resultados: La revisión de la literatura fue referente para la construcción del instrumento. En la segunda fase el 87% de los participantes no conocían el concepto off label, el 65% fueron profesionales de la enfermería que describieron su experiencia como una práctica que no se podría considerar como off label por la falta de soporte científico. Los medicamentos antiinfecciosos, antifúngicos, analgésicos y electrolitos, fueron los grupos de mayor utilización. La principal modificación fue en el cambio de la vía de administración, seguido de la indicación y el 71% de las prácticas no fue descrita en los registros clínicos. Conclusiones: Existe limitada evidencia que soporte el uso de medicamentos en vías y condiciones no establecidos en la ficha técnica; no existe una definición clara y común, presentándose un desconocimiento en los profesionales de la salud.


Identify the knowledge and practices of the health personnel regarding the use of medicine different from the procedures and conditions established in the medical fact sheet. Method: Quantitative study of descriptive and cross-sectional type: the first consisted of a review of the literature where 82 articles were initially included, from which eight were selected for review; the second one was made by 31 participants who worked at healthcare institutions; these were selected by sequential sampling, and a questionnaire was used to identify the knowledge and practices developed, the questionnaire was evaluated by 3 expert professors; a pilot experiment was also made. Results: The review of the literature was a reference to build the instrument. On the second phase, 87% of the participants did not know the concept off label, and 65% were nursing professionals who described their experience as a practice that cannot be considered off label due to the lack of scientific support. The anti-infective, anti-fungal, analgesics and electrolytes were the most used drugs. The main adjustment was the administration procedure, followed by the indications, and 71% of the practices were not described in the case report form. Conclusions: There is limited evidence that supports the use of medicine different from the procedures and conditions that are not established in the medical fact sheet; there is no clear and common definition, implicating unknowingness of the healthcare professionals.


Identificar conhecimentos e práticas do pessoal de saúde respeito ao uso de medicamentos em vías e condições diferentes às estabelecidas na bula. Método: Estudo quantitativo, descritivo de corte transversal realizado em duas fases: a primeira, realizou-se uma revisão da literatura onde incluíram- se inicialmente 82 artigos, dos quais 8 elegeram-se para a revisão; a segunda fase, estudou 31 participantes trabalhadores do setor saúde selecionados de maneira não probabilística sequencial aplicando-se um questionário para estabelecer os conhecimentos e práticas desenvolvidas, avaliado previamente por 3 professores expertos na temática; também foi realizada uma prova piloto. Resultados: A revisão da literatura esteve relacionada com a construção do instrumento. Na segunda fase o 87% dos participantes não conhecia o conceito off label pela ausência de suporte científico. Os medicamentos antibacterianos, antifúngicos, analgésicos e eletrólitos foram os de maior utilização. A principal modificação foi a mudança na via de administração, seguido da indicação e o 71% das práticas não foram registradas no prontuário. Conclusões: Existe limitada evidencia que suporte o uso de medicamentos nas vias e condições não estabelecidas na bula; não existe definição clara e comum, presentando-se o desconhecimento nos profissionais da saúde.


Subject(s)
Drug Utilization , Pharmaceutical Preparations , Drug Therapy , Off-Label Use
9.
Blood Research ; : 49-56, 2020.
Article in English | WPRIM (Western Pacific) | ID: wprim-820803

ABSTRACT

BACKGROUND: Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma (PBL) is a rare entity of diffuse large B-cell lymphoma (DLBCL). The clinicopathological features of and optimal treatment for HIV-negative PBL remain largely unknown.METHODS: To gain insight into this distinct lymphoma, we summarized the clinicopathologic characteristics of 8 unpublished HIV-negative PBLs and performed a comprehensive review of 394 published cases.RESULTS: Of the 8 unpublished PBLs, the median patient age was 53.0 years. Four patients presented with stage IV disease. All 8 patients showed a plasma cell-like immunophenotype. Of the six patients who received anthracycline-based chemotherapy, including two who received bortezomib, three patients achieved a continuous complete response, two patients died due to disease progression, and one patient was lost to follow-up. The other two patients achieved continuous complete response after receiving chemotherapy combined with radiotherapy and surgery. Of the 402 patients, the majority were male, with a mean age of 58.0 years. EBV infection was detected in 55.7% of the patients. The median survival times of the patients who received CHOP or CHOP-like regimens and intensive regimens were not reached and 23.0 months, respectively, and the intensive regimen did not improve the survival outcome (P=0.981). Multivariate analysis showed that EBER remained the only independent factor affecting overall survival (OS).CONCLUSION: HIV-negative PBL is a distinct entity with a predilection for elderly and immunosuppressed individuals. Intensive chemotherapy had no apparent survival benefits over the CHOP regimen in terms of OS; the prognosis of this disease is poor with current chemotherapy methods, and treatment remains a challenge.


Subject(s)
Aged , Bortezomib , Disease Progression , Drug Therapy , Epstein-Barr Virus Infections , HIV , Humans , Lost to Follow-Up , Lymphoma , Lymphoma, B-Cell , Male , Multivariate Analysis , Plasma , Plasmablastic Lymphoma , Prognosis , Radiotherapy
10.
Article in English | WPRIM (Western Pacific) | ID: wprim-816636

ABSTRACT

Coccidiosis-causing Eimeria species are transmitted in poultry via the oral-fecal route and can lead to hemorrhagic diarrhea and mortality. This results in enormous economic losses in the poultry industry. Furthermore, its resistance to some currently used antibiotics is increasing. This has prompted the development of new alternative drug therapies that address the issue of chemical-free meat production. Effective management of infectious diseases in veterinary practice includes the induction of protective and adaptive immunity by treatment with an alternative agent. In this study, we evaluated the anticoccidial effects of dietary supplementation of Chosun University (CS) 32 compounds (0.1% and 1.0%) against Eimeria tenella, which was isolated and purified from the supernatant of culture broth of Bacillus strain (KCTC18250P), as well as its effect on the growth rate and feed efficiency in chickens. Overall, we observed a decrease in lesion scores and oocyte output in CS 32 compounds-treated chickens. We concluded that 0.1% CS 32 compounds displayed anticoccidial effects against E. tenella infection.


Subject(s)
Adaptive Immunity , Anti-Bacterial Agents , Bacillus , Chickens , Communicable Diseases , Diarrhea , Dietary Supplements , Drug Therapy , Eimeria tenella , Eimeria , Meat Products , Mortality , Oocytes , Poultry
11.
Article in Korean | WPRIM (Western Pacific) | ID: wprim-811241

ABSTRACT

OBJECTIVES: To compare the clinical effectiveness of the virtual reality (VR) programs in assessing psychosocial problems, improving symptoms, and reducing suicide risk in depressive patients with those of pharmacotherapy.METHODS: Thirty-six patients were recruited with depression in the treatment group and 22 participants in the healthy control group through internet advertisements between November 2018 and March 2019. Participants in the treatment group were allocated randomly at a 1:1 ratio to either the VR group or pharmacotherapy group. At the baseline, all participants were assessed with a comprehensive battery for their psychological characteristics by structured scales using VR technologies. Assessments of patients in the treatment group were repeated four weeks after therapeutic intervention. The primary outcome measures were the Korean Version of Quick Inventory of Depressive Symptomatology-Self-Report and suicidality scales of the Korean Mini International Neuropsychiatric interview. The borderline personality (Personality Assessment Inventory-Borderline Features Scale) and resilience (Korean Resilience Questionnaire) were also evaluated.RESULTS: Twenty-four depressive patients completed the treatment, and the final assessment was conducted after four weeks of treatment. In the initial assessment, the patient group showed significantly higher depressive symptoms, suicidality, borderline personality trait, and lower resilience than healthy control group. After the four-week therapeutic interventions, the VR group showed significant improvement in depression, suicidality, borderline personality trait, and resilience. In addition, there was no significant difference in the treatment efficacy between the VR group and the pharmacotherapy group.CONCLUSION: In this study, the VR treatment program has clear benefits for emotional distress and reducing suicidality in depressive patients. Evidence-based VR treatments may show new clinical potential for depressive disorder.


Subject(s)
Depression , Depressive Disorder , Drug Therapy , Education , Humans , Internet , Outcome Assessment, Health Care , Psychotherapy , Suicidal Ideation , Suicide , Treatment Outcome , Weights and Measures
12.
Article in English | WPRIM (Western Pacific) | ID: wprim-811220

ABSTRACT

OBJECTIVE: Neoadjuvant chemotherapy (NACT) for the treatment of epithelial ovarian cancer (EOC) has remained controversial. This meta-analysis was performed to systematically assess the efficacy and safety of NACT versus primary debulking surgery (PDS) in patients with EOC.METHODS: PubMed, Embase, ClinicalTrials.gov, and Cochrane Library were queried to assess the therapeutic value of NACT versus PDS in EOC. Electronic databases were queried by using the keywords “ovarian cancer/neoplasms”, “primary debulking surgery”, and “neoadjuvant chemotherapy”.RESULTS: The available trials were pooled, and hazard ratios (HRs), relative risk ratios (RRs) and associated 95% confidence intervals (95% CIs) were determined. Sixteen trials involving 57,450 participants with EOC (NACT, 9,475; PDS, 47,975) were evaluated. We found that NACT resulted in markedly decreased overall survival than PDS in patients with EOC (HR=1.30; 95% CI=1.13–1.49; heterogeneity: p<0.001, ²=82.7%). Furthermore, our results demonstrated that the NACT group displayed increased completeness of debulking removal (RR=1.69, 95% CI=1.32–2.17; heterogeneity: p<0.001, ²=81.9%), and reduced risk of postsurgical death (RR=0.18, 95% CI=0.06–0.51; heterogeneity: p=0.698, ²=0%) and major infection (RR=0.29, 95% CI=0.17–0.51; heterogeneity: p=0.777, ²=0%) compared with patients administered PDS.CONCLUSIONS: This meta-analysis indicated that NACT results in increased completeness of debulking removal, and reduced risk of postsurgical death and major infection compared with PDS, while PDS is associated with improved survival in comparison with NACT in EOC patients.TRIAL REGISTRATION: PROSPERO Identifier: CRD42019120625


Subject(s)
Cytoreduction Surgical Procedures , Drug Therapy , Humans , Neoadjuvant Therapy , Odds Ratio , Ovarian Neoplasms , Population Characteristics
13.
Article in English | WPRIM (Western Pacific) | ID: wprim-811217

ABSTRACT

OBJECTIVE: To evaluate the effectiveness and safety of the combination of pegylated liposomal doxorubicin with carboplatin (CD) compared with those of carboplatin and paclitaxel (CP) for platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer in a real-world setting in Korea.METHODS: We enrolled relevant patients from 9 institutions. All patients received CD or CP as the second- or third-line chemotherapy in routine clinical practice during 2013–2018. The primary endpoints were progression-free survival (PFS) and toxicity. The secondary endpoint included the objective response rate (ORR).RESULTS: Overall, 432 patients (224 and 208 in the CD and CP groups, respectively) were included. With a median follow-up of 18.9 months, the median PFS was not different between the groups (12.7 vs. 13.6 months; hazard ratio, 1.161; 95% confidence interval, 0.923–1.460; p=0.202). The ORR was 74.6% and 80.1% in the CD and CP group, respectively (p=0.556). Age and surgery at relapse were independent prognostic factors. More patients in the CD group significantly experienced a grade 3 to 4 hematologic toxicity and hand-foot syndrome (13.8% vs. 6.3%), whereas grade 2 or more alopecia (6.2% vs. 36.1%), peripheral neuropathy (4.4% vs. 11.4%), and allergic/hypersensitivity reaction (0.4% vs. 8.5%) developed more often in the CP group.CONCLUSIONS: The safety and effectiveness of chemotherapy with CD in a real-world setting were consistent with the results from a randomized controlled study. The different toxicity profiles between the 2 chemotherapy (CD and CP) regimens should be considered in the clinical practice.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03562533


Subject(s)
Alopecia , Carboplatin , Cohort Studies , Disease-Free Survival , Doxorubicin , Drug Therapy , Follow-Up Studies , Hand-Foot Syndrome , Humans , Korea , Ovarian Neoplasms , Paclitaxel , Peripheral Nervous System Diseases , Platinum , Prognosis , Recurrence , Retrospective Studies
14.
Article in English | WPRIM (Western Pacific) | ID: wprim-811214

ABSTRACT

OBJECTIVE: The causal association of human papillomavirus (HPV) in uterine cervical cancer was well established and this oncogenic virus was reported to be a biomarker for overall recurrence and central pelvic recurrence. The objective of the present systematic review and meta-analysis was to assess the role of HPV DNA testing in early detection of recurrence among cervical cancer survivors after radiotherapy.METHODS: We performed a systematic review and meta-analysis by means of searching electronic databases for published articles between January 1984 and June 2018, on the basis of standard systematic review guidelines prescribed by major agencies namely Cochrane Collaboration (https://www.cochrane.org) and Campbell Collaboration (https://www.campbellcollaboration.org). The meta-analysis component was further modified appropriately for the synthesis of sensitivity and specificity results.RESULTS: A total of 1,055 cervical cancer cases who had received pelvic radiation with or without chemotherapy from ten cohort studies were evaluated. The overall pooled sensitivity and specificity of HPV DNA testing was 0.84 (95% confidence interval [CI]= 0.66–0.94) and 0.35 (95% CI=0.20–0.54) respectively. The positive likelihood ratio was 1.3 (95% CI=1.0–1.7) and the negative likelihood ratio was 0.45 (95% CI=0.18–1.10) with an estimated diagnostic odds ratio of 3 (95% CI=1–9).CONCLUSION: The screening for HPV DNA testing during follow-up facilitates early detection of recurrence after radiotherapy.


Subject(s)
Cervix Uteri , Cohort Studies , Cooperative Behavior , DNA , Drug Therapy , Female , Follow-Up Studies , Human Papillomavirus DNA Tests , Humans , Mass Screening , Odds Ratio , Oncogenic Viruses , Radiotherapy , Recurrence , Sensitivity and Specificity , Survivors , Uterine Cervical Neoplasms
15.
Article in English | WPRIM (Western Pacific) | ID: wprim-811212

ABSTRACT

OBJECTIVE: To compare the efficacy and toxicity of dose-dense weekly paclitaxel and 3-weekly carboplatin (ddPC) as neoadjuvant chemotherapy (NAC) with the standard 3-weekly regimen.METHODS: A retrospective study of patients diagnosed with stage IIIc and IV ovarian cancer who received at least one cycle of NAC followed by interval debulking surgery between August 2015 and January 2018 was conducted. Patient characteristics, clinical and pathological response to NAC, surgical and survival outcome, and adverse event were compared.RESULTS: A total of 23 patients in the ddPC group and 50 patients in the standard group received a median of 3 cycles of NAC. Rate of grade ≥3 neutropenia was significantly higher in the ddPC group than the standard (82.6% vs. 22.0%, p<0.001). Patients in the ddPC group underwent dose-reduction more frequently (34.8% vs. 4.00%, p=0.001). Normalization of cancer antigen-125 post-NAC occurred more frequently in the ddPC group (73.9% vs. 46.0%, p=0.030). No residual disease rate (43.5% vs. 60.0%, p=0.188) and chemotherapy response score of 3 (34.8% vs. 26.0%, p=0.441) were not statistically different between two groups. There was no statistical difference in progression free survival (PFS) at 2 years (36.3% vs. 28.4%, p=0.454). Cox proportional hazard model showed that ddPC was not a significant determinant of PFS (p=0.816).CONCLUSION: There was no difference between both regimens in terms of NAC response and survival outcomes. However, ddPC group showed higher hematologic toxicity requiring dose reduction.


Subject(s)
Carboplatin , Disease-Free Survival , Drug Therapy , Humans , Neoadjuvant Therapy , Neutropenia , Ovarian Neoplasms , Paclitaxel , Proportional Hazards Models , Retrospective Studies , Treatment Outcome
16.
Article in English | WPRIM (Western Pacific) | ID: wprim-782278

ABSTRACT

BACKGROUND: The Occupational Safety and Health Research Institute (OSHRI) of the Korea had not recognized gastrointestinal cancer as work-related disease during their evaluation. However, in 2018 OSHRI recognized gastric and rectal cancers as work-related disease in asbestos-exposed workers. We present 2 such cases along supportive evidence of causation.CASE PRESENTATION: Patient A: A 57-year-old man had worked for about 40 years since 1978 as an oxygen cutter at workplaces that dismantle ships, buildings, boilers, and thermal power plants. In November 2016, endoscopy and biopsy confirmed the diagnosis of advanced gastric cancer, for which he underwent subtotal gastrectomy and chemotherapy; however, he later died of the cancer. Patient B: A 71-year-old man had worked in shipbuilding and repair workplaces for approximately 49 years, being employed in pipe laying, asbestos insulation installation, grinding, and other ship repair work. In 2003, he was diagnosed of rectal cancer by abdominal computed tomography. He accordingly underwent surgical removal of the cancer. Based on the occupational history of the 2 patients and our review of the relevant literature addressing the occupational environment, we concluded that both patients had continuous exposure to high levels of asbestos while performing their jobs for 40 and 49 years, respectively.CONCLUSION: Both patients had a history of smoking and drinking (non-occupational personal risk factors). However, the possibility of an increased risk of gastric and rectal cancers from asbestos exposure cannot be excluded. Therefore, we considered that occupational exposure to asbestos had contributed to the cancer diagnosis in these cases. Workers exposed to asbestos should be made aware of the possibility of gastric or rectal cancer, and should undergo monitoring and medical examinations. Appropriate compensation for gastric and rectal cancers that occur in workers exposed to asbestos are anticipated in future.


Subject(s)
Academies and Institutes , Aged , Asbestos , Biopsy , Compensation and Redress , Diagnosis , Drinking , Drug Therapy , Endoscopy , Gastrectomy , Gastrointestinal Neoplasms , Humans , Korea , Middle Aged , Occupational Exposure , Occupational Health , Oxygen , Power Plants , Rectal Neoplasms , Ships , Smoke , Smoking , Stomach Neoplasms
17.
Article in English | WPRIM (Western Pacific) | ID: wprim-782209

ABSTRACT

OBJECTIVE: This study aimed to investigate the potential predictive factors for platinum resistance and poor prognosis in epithelial ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-based chemotherapy.METHODS: Medical records of 306 patients with the above mentioned cancers treated with platinum-based chemotherapy between 2007 and 2017 were retrospective reviewed. Clinical data, preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platinum-free interval, and survival time were recorded. NLR, PLR, and cancer antigen 125 (CA125) levels were calculated for an optimal cutoff point using receiver operating characteristic curves. The clinicopathological variables were compared using univariate and multivariate analyses to identify independent predictive factors for platinum resistance and poor survival outcomes.RESULTS: The optimal cutoff points for NLR, PLR, and CA125 were 3.38, 210, and 365 IU/L, respectively. Univariate analysis indicated that NLR >3.38, PLR >210, CA125 >365, advanced stage, suboptimal disease, serous type, and ascites were significant predictive factors for platinum resistance. However, only NLR >3.38 and advanced stage were independent predictive factors with an adjusted odds ratio of 1.880 and 3.333, respectively. Regarding factors associated with poor survival outcomes, only PLR >210 and advanced stage were independent factors, with a hazard ratio of 1.578 and 3.994, respectively.CONCLUSION: High NLR and advanced stage were potential independent predictive factors for platinum resistance, whereas high PLR and advanced stage were potential independent predictive factors for poor survival outcomes.


Subject(s)
Ascites , Blood Platelets , Drug Therapy , Fallopian Tubes , Female , Humans , Lymphocytes , Medical Records , Multivariate Analysis , Neutrophils , Odds Ratio , Ovarian Neoplasms , Platinum , Prognosis , Retrospective Studies , ROC Curve
18.
Article in English | WPRIM (Western Pacific) | ID: wprim-782208

ABSTRACT

OBJECTIVE: Epithelial ovarian cancer (EOC) requires an aggressive surgical approach. The important part of literature on ovarian cancer surgery emphasize residual tumor and survival analyses. Morbidity issue keeps in background. Therefore, we aimed to report on morbidity of cytoreductive surgery for EOC in this study.METHODS: EOC patients who underwent primary debulking were evaluated. Intraoperative and postoperative complications that occurred within 30 days after the surgery and factors that affect morbidity were considered.RESULTS: The study involved 359 patients. Forty-six intraoperative complications occurred in 42 (11.6%) patients. Advanced stage and cancer antigen level of 125 were independently and significantly associated with operative complications (hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.01–2,73; P=0.044, and HR, 1.47; 95% CI, 1.05–2.06; P=0.025, respectively). The need for intensive care unit admission was significantly higher in patients with intraoperative complications (28.6% vs. 8.8%, P=0.001). Intraoperative and postoperative complication rates were significantly higher in extended surgery than in standard surgery (18.9%vs. 8.5%, P=0.005 and 38.7% vs. 10.9%, P < 0.001, respectively). Intraoperative and postoperative transfusion need, hospital stay duration, and chemotherapy start day were also significantly higher in extended surgery than in standard surgery. Hundred postoperative complications occurred in 70 patients. Age, extended surgery, presence of ascites, and presence of operative complications were independently and significantly associated with postoperative complications.CONCLUSION: Morbidity of extensive surgical approach should be kept in mind in ovarian cancer surgery aimed at leaving no residual tumor. Patient-based management with an appropriate preoperative evaluation may avoid morbidity of extended/extensive surgical approaches.


Subject(s)
Ascites , Drug Therapy , Humans , Intensive Care Units , Intraoperative Complications , Length of Stay , Neoplasm, Residual , Ovarian Neoplasms , Postoperative Complications
19.
Article in English | WPRIM (Western Pacific) | ID: wprim-782203

ABSTRACT

Müllerian anomalies are rare deformities in women, and only a few cases concerning gynecologic malignancies arising in patients with congenital uterine malformations have been reported. Herein, we present the case of a 34-year-old woman with dysgerminoma with a Müllerian anomaly (uterus didelphys). She had secondary amenorrhea, and an ovarian mass and uterus didelphys were discovered during examination. After right salpingo-oophorectomy, the tumor was confirmed as dysgerminoma, and a chromosome study revealed a normal female karyotype (46, XX). The patient completely responded to 6 cycles of chemotherapy. To our knowledge, this is the first reported case of dysgerminoma with uterus didelphys. Although gynecologic malignancies in patients with Müllerian anomalies are very rare, clinicians should be aware of the coexistence of gynecologic malignancies and uterine malformations.


Subject(s)
Adult , Amenorrhea , Congenital Abnormalities , Drug Therapy , Dysgerminoma , Female , Humans , Karyotype , Uterus
20.
Yonsei Medical Journal ; : 15-19, 2020.
Article in English | WPRIM (Western Pacific) | ID: wprim-782128

ABSTRACT

PURPOSE: The purpose of this study was to assess the diagnostic and prognostic value of serum progastrin-releasing peptide (ProGRP) in patients with gastric cancer (GC).MATERIALS AND METHODS: A total of 150 patients with GC (89 males and 61 females) were recruited, including those with stage I (n=28), stage II (n=33), stage III (n=50), and stage IV (n=39) disease; 50 healthy controls and 66 patients with benign gastric diseases were also enrolled. Levels of serum ProGRP, carcinoembryonic antigen (CEA), and carbohydrate antigen 72-4 (CA72-4) were measured in all subjects.RESULTS: Serum ProGRP levels were significantly higher in GC patients than in controls (p<0.001), and ProGRP was significantly correlated with tumor size, tumor node metastasis stage, differentiation, invasion depth, and lymph node metastasis (p< 0.005). ProGRP levels were significantly decreased after chemotherapy (p<0.001). Receiver operating characteristic curves revealed a sensitivity and specificity for serum ProGRP in GC of 85.9% and 81.2%, respectively. ProGRP levels were positively correlated with CA72-4 and CEA (r=0.792 and 0.688, p<0.05, respectively). Combined detection of ProGRP, CEA, and CA72-4 showed the best diagnostic power for GC.CONCLUSION: ProGRP may be useful as a potential biomarker for GC diagnosis and therapy.


Subject(s)
Carcinoembryonic Antigen , Diagnosis , Drug Therapy , Humans , Lymph Nodes , Male , Neoplasm Metastasis , ROC Curve , Sensitivity and Specificity , Stomach Diseases , Stomach Neoplasms
SELECTION OF CITATIONS
SEARCH DETAIL